The pharmaceutical and biotechnology sector experienced at least 12 confirmed bankruptcy filings in 2025 through November, continuing the elevated distress levels from 2023-2024's record-breaking years. This wave of insolvencies stems from a perfect storm of tight capital markets, rising debt service costs, clinical trial failures, and regulatory uncertainty. The bankruptcies span from early-stage gene therapy developers to commercial-stage diagnostics companies, with total liabilities exceeding $1 billion across all filings.
Industry experts describe the trend as just "the tip of the iceberg," with many more biotechs quietly dissolving through less visible Alternative Business Closure proceedings. The funding drought has proven particularly brutal for capital-intensive fields like cell and gene therapy, where companies like ASC Therapeutics filed for liquidation despite FDA clearance and active Phase 1 trials. Even major partnerships couldn't save some firms—Omega Therapeutics collapsed just 13 months after signing a $532 million deal with Novo Nordisk.
The crisis reflects a broader market correction following the pandemic-era funding boom. Between 2020-2021, biotechs raised unprecedented capital at elevated valuations and took on debt at near-zero interest rates. As rates climbed and public markets soured on biotech, companies faced a funding cliff. Venture capital for biotechs plummeted from $7 billion in Q1 2025 to just $4.8 billion in Q2—the lowest in three years. Series B rounds became particularly challenging, with one VC partner describing them as "the hardest asset class to raise for across any industry right now."
Filing date: February 10, 2025
Type: Chapter 11 (Delaware)
Assets/Liabilities: $137.5 million / $140.4 million
The Cambridge-based epigenomic medicine developer, founded by Flagship Pioneering in 2017, filed for bankruptcy after Banc of California swept $14.66 million from company accounts on January 13, 2025 following a loan default declaration. This left Omega without operating capital despite a promising obesity partnership with Novo Nordisk signed just 13 months earlier.
Pipeline at collapse: Omega's platform used programmable epigenomic mRNA medicines to modulate gene expression without altering DNA. Lead program OTX-2002 targeted c-MYC oncogene regulation for hepatocellular carcinoma and had shown a 50% disease control rate in Phase 1, but the company halted the trial in November 2024 due to funding constraints. The Novo Nordisk collaboration aimed to enhance thermogenesis for obesity treatment through controlled epigenomic modulation, with potential milestone payments up to $532 million—but only $5.1 million came upfront.
Why it failed: The company had already cut 35% of its workforce in March 2024 to extend its cash runway into Q1 2025. Despite going public in August 2021 at a $866 million valuation ($17/share), shares traded at just $0.22 by filing time. Nasdaq delisted the stock for failing to maintain the $1 minimum bid price. Net losses totaled $73.1 million in the 12 months through September 2024.
Outcome: Flagship Pioneering's Pioneering Medicines 08-B served as stalking horse bidder with a $9.92 million DIP financing package. The bankruptcy court approved asset sales on April 23, 2025 for $14 million total, with the plan becoming effective July 18, 2025 as a liquidating entity.
Filing date: March 21, 2025
Type: Chapter 7 liquidation (Delaware)
Assets/Liabilities: Minimal assets / Undisclosed liabilities
The Houston-based developer of allogeneic Gamma Delta T (GDT) cell therapies for solid tumors ceased all operations and filed for Chapter 7 liquidation after funding negotiations with major investor Shannon Ralston collapsed.
Pipeline at collapse: Deltacel-01 was in Phase 1 clinical trials for non-small cell lung cancer, combining the company's GDT cell technology with low-dose targeted radiation. The trial had achieved impressive results—Patient 4 reached 15-month progression-free survival. Additional programs included Isocel for Mesothelin Isoform 2 positive solid malignancies and Procel for PD-L1 positive solid malignancies, both evaluated in ALEXIS clinical trials.
Why it failed: Founded in 2006 and operating for nearly two decades, Kiromic's current ratio plummeted to 0.16, indicating severe liquidity crisis. Stock prices fell over 65% in the year preceding bankruptcy, leaving market capitalization at just $1.49 million. When funding negotiations with Ralston stalled in March 2025, creditor law firm Steptoe filed an action in Delaware Chancery Court seeking receiver appointment, triggering the Chapter 7 filing.
Outcome: The entire Board of Directors resigned at filing. All top executives were terminated, including CFO Brian Hungerford, COO Leonardo Mirandola, and Chief of Staff Scott Dahlbeck. Shannon Ralston's subsidiaries—S.hield Cap1tal Funding LLC and Immunocell Therapeutics, Inc.—purchased the assets on April 14, 2025 (court-approved) to continue clinical trials.
Filing date: March 24, 2025
Type: Chapter 11 (Missouri federal court)
Assets/Liabilities: Estimated $100-500 million range for both
The pioneering direct-to-consumer genetics company filed for bankruptcy protection after its stock collapsed from a $6 billion market cap at its 2021 SPAC IPO to under $50 million by March 2025.
Pipeline at collapse: 23andMe had pivoted to drug development using its database of 13.4+ million genotyped individuals (80% consented to research). Lead programs included 23ME-00610, an immune checkpoint inhibitor targeting CD200R1 in Phase 1/2 trials for multiple solid tumor types including neuroendocrine cancers, kidney cancer, and small cell lung cancer. The company also advanced 23ME-01473, a dual-mechanism antibody targeting ULBP6 in Phase 1 for advanced solid tumors that activates both NK cells and T cells. A prolific GSK collaboration initiated in 2018 generated 50+ programs, with 23andMe holding royalty rights to GSK6097608 (CD96-targeting antibody) and multiple other GSK programs.
Why it failed: The consumer genetic testing business declined precipitously as market saturation hit. CEO Anne Wojcicki's multiple privatization offers (final bid $2.53/share or $74 million) were rejected by the board. The entire independent board resigned in September 2024 in protest. The company shut down its therapeutics division in November 2024 with a 40% workforce reduction (200+ employees), despite the strong drug discovery pipeline. Stock traded at $0.88 at filing.
Outcome: CEO Wojcicki resigned to become an independent bidder. Regeneron Pharmaceuticals emerged as the successful bidder in May 2025, acquiring the company for $256 million in a bankruptcy auction. Regeneron plans to continue the consumer business while leveraging the genetic database for drug development with strengthened privacy protections.
Filing date: April 20, 2025
Type: Chapter 11 (Delaware)
Assets/Liabilities: $2.5 million / $29.4 million
The Austin-based developer filed for reorganization after becoming unable to service its debt despite two decades of operations since its 2001 founding.
Pipeline at collapse: Molecular Templates developed Engineered Toxin Bodies (ETBs) using genetically engineered Shiga-like Toxin A subunits to target cancer. Active programs included MT-8421 (Phase 1 for dismantling tumor microenvironment), MT-0169 (Phase 1 for relapsed/refractory multiple myeloma), and MT-6402 (Phase 1 for PD-L1 expressing tumors). The company maintained a collaboration with Bristol Myers Squibb for novel ETB products.
Why it failed: The company's interest burden expanded more than 10x from 2020-2021 levels by the end of 2023, reflecting how pandemic-era debt at low rates became unsustainable as rates climbed. Despite selling its engineered cell business in spring 2024 (reducing operating losses by one-third), Molecular Templates still couldn't generate positive cash flow by February 2025. With headquarters in Austin and operations in Foxboro, Massachusetts, the company had dual-site overhead costs.
Outcome: Lender K2 HealthVentures LLC provided $6.5 million in DIP financing ($500,000 new money, $6 million roll-up) at 13.5% interest. The reorganization plan involved a debt-for-equity swap where K2 exchanged $15 million in prepetition secured claims for 100% of the reorganized company's equity. All existing common and preferred stock was canceled, leaving nothing for unsecured creditors after administrative expenses. The plan was confirmed July 7, 2025, becoming effective July 18, 2025.
Filing date: April 2, 2025
Type: Chapter 7 liquidation (Eastern District of Pennsylvania)
Assets/Liabilities: $0-50,000 / Over $1 million
The Honey Brook, Pennsylvania-based distributor filed for liquidation after 20 years in business, ending a business model focused on distributing name-brand pharmaceutical drugs at generic prices.
Products: Provell marketed Euthyrox (levothyroxine sodium) in blister packaging for hypothyroidism treatment. In March 2024, the company announced a partnership with Mark Cuban Cost Plus Drug Company to expand access to cost-effective medications. The company was 72% owned by Swedish investment company Flerie AB, which had already written off the entire value of its holding.
Why it failed: Attorney Edmond George cited "financial issues with drug supplier" as the primary cause. With fewer than 10 employees in 2024, no sales team, and minimal assets, Provell couldn't compete with larger distributors or maintain stable supply chain relationships in an increasingly consolidated market.
Filing date: May 5, 2025
Type: Chapter 11 (Delaware)
Assets/Liabilities: $50-100 million / $100-500 million
Founded in 2012 by former SpaceX engineers Paul Dabrowski, Michael Dabrowski, and Alex Pesch, the Redwood City-based CRISPR tools provider filed despite raising $392 million in venture capital over its lifetime.
Products and services: Synthego manufactured synthetic guide RNAs (sgRNAs), engineered cells, and screening libraries as part of its CRISPRevolution Portfolio. The company operated two GMP-compliant manufacturing facilities and served an impressive customer base: 25% large pharma/biotech companies, 50% small/mid-sized biotech firms, and 25% academic medical centers. Approximately 25% of the ~1,000 global cell and gene therapy companies used Synthego products. A partnership with AstraZeneca announced in January 2025 featured the eSpOT-ON CRISPR Enzyme.
Why it failed: Despite strong revenue growth from 2020-2023, the company suffered severe margin compression. High investment costs in technology development and dual GMP facility operations became unsustainable. The company sold its engineered cell business in 2024, reducing losses by one-third, but remained cash-flow negative through February 2025. The debt service burden proved insurmountable—interest costs ballooned while the company couldn't achieve profitability. An ongoing patent dispute with Agilent Technologies added legal costs and uncertainty.
Outcome: Perceptive Advisors provided $50 million in DIP financing ($12.5 million new money, $37.5 million roll-up) and emerged as the stalking horse bidder with a credit bid up to $85 million in debt. Allen Soong from Paladin Management Group was appointed Chief Restructuring Officer. Raymond James conducted a court-supervised auction, with the sale expected to close by July 14, 2025 (70 days post-filing).
Filing date: July 6, 2025
Type: Chapter 11 (Delaware)
Assets/Liabilities: $50 million / $100-500 million
This contract development and manufacturing organization (CDMO) filed for bankruptcy after government contracts wound down post-pandemic, leaving the company unable to replace the revenue with commercial work.
Services and facilities: Operating a 183,000 square foot Advanced Development Manufacturing Facility in Alachua, Florida, plus a 92,000 square foot expansion (Building G), the company specialized in biologics including vaccines, monoclonal antibodies, recombinant proteins, and nucleic acids. The facilities housed approximately 800 pieces of government-owned equipment from the Department of Defense and other agencies. Founded in 1999, Alachua held a 2013 greenfield contract with the U.S. Department of Defense and secured a major February 2020 contract for COVID-19 monoclonal antibody therapy.
Why it failed: Demand for services declined sharply in late 2023 as government contracts scaled back or terminated. The company laid off 125 employees between January-April 2025, followed by 67 more in June-July 2025, leaving only 16 employees (13 full-time, 3 temporary) at the petition date—an 80% workforce reduction from 240 employees. Failed attempts to secure commercial contracts to replace government business led to severe financial distress.
Major creditors: United States International Development Finance Corp. ($246 million), Defense Contract Management Agency ($11.95 million), Sigma-Aldrich Inc. ($1.33 million).
Outcome: Investment bank Jefferies LLC was engaged in February 2025 to market the assets. The process generated 16 introductory calls and 24 signed NDAs, yielding 4 indications of interest by the July 29 stalking horse deadline. However, uncertainty over removal of the 800+ pieces of government-owned equipment complicated the sale process. The court appointed a creditors committee on July 23, 2025 (represented by Goodwin Procter LLP and Robinson & Cole LLP). JMB Capital Partners Lending, LLC provided DIP financing. The company set an October 15, 2025 sale deadline.
Filing date: September 23, 2025
Type: Chapter 11 (District of New Jersey)
Assets/Liabilities: Not disclosed / "Tens of millions of dollars" owed by insurers
The parent company ProPhase Labs (NASDAQ: PRPH) filed bankruptcy for three COVID-19 testing laboratory subsidiaries only, while continuing to operate its other businesses and exploring a cryptocurrency treasury strategy.
Services: The three subsidiary units provided COVID-19 testing services during and after the pandemic.
Why it filed: This represented a strategic bankruptcy filing aimed at accelerating recovery of "tens of millions of dollars" collectively owed by insurance companies for testing services provided. Insurance companies failed to pay for services rendered, leaving the units with massive outstanding receivables but insufficient working capital.
Unique context: On September 9, 2025, stockholders approved proposals allowing the parent company to invest in cryptocurrency as part of a treasury diversification strategy. The bankruptcy filing was strictly limited to the three testing lab subsidiaries, while ProPhase Labs itself remained operational and solvent, viewing Chapter 11 as a tool to force payment collection from insurers.
Filing date: November 15, 2025 (filed); November 19, 2025 (announced publicly)
Type: Chapter 11
Stock price at filing: $0.37 per share
The New York-based clinical-stage biotech filed for bankruptcy protection after its lead program for amyotrophic lateral sclerosis (ALS) failed in Phase 2/3 trials.
Pipeline at collapse: SLS-005, the company's lead asset for ALS, missed its primary endpoint in a Phase 2/3 trial in March 2025—described as the "beginning of the end" for the company. The company had also advanced SLS-002, an intranasal ketamine formulation for post-traumatic stress disorder (PTSD), signing a material transfer agreement with the U.S. Army Medical Materiel Development Activity for PTSD testing in September 2025, just weeks before the bankruptcy filing.
Why it failed: The March 2025 clinical failure of SLS-005 destroyed investor confidence and the company proved unable to secure additional financing. The stock moved from OTCQB to the OTC Pink Market (the lowest tier). Multiple postponements of the annual stockholders' meeting occurred due to lack of quorum. The company executed a massive reverse stock split in September 2025 (50 million shares consolidated to 3.125 million). SEC 10-Q filings were delayed due to bankruptcy preparation and "staffing issues."
Outcome: The company filed for voluntary Chapter 11 bankruptcy with 120 days to develop a reorganization plan. Operations continue under bankruptcy court jurisdiction while exploring strategic alternatives.
Filing date: November 19, 2025
Type: Chapter 7 liquidation
Assets/Liabilities: $100,000-500,000 / $10-50 million
The Milpitas, California-based gene and cell therapy developer filed for complete liquidation despite having an active Phase 1/2 clinical trial and FDA clearances.
Pipeline at collapse: ASC618, a second-generation AAV8-based gene therapy for hemophilia A, received FDA IND clearance in mid-2021, FDA Fast Track Designation, FDA Orphan Drug Designation, and a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products. The company dosed its first patient at Arkansas Children's Hospital in January 2024. The therapy used a novel liver-specific promoter and bioengineered, codon-optimized B domain-deleted FVIII variant (ET3) showing 10-fold increase in biosynthesis and secretion versus standard constructs.
ASC930, a decidua stromal cell (DSC) therapy, was in Phase 2b trials for steroid-refractory acute graft-versus-host disease in bone marrow transplant patients, having received FDA Orphan Drug Designation in 2021. The company also partnered with UMass Chan Medical School researchers for a Maple Syrup Urine Disease gene therapy program in IND-enabling studies, having demonstrated safety and efficacy in murine and bovine models.
Why it failed: The catastrophic debt-to-asset ratio (up to $50 million in liabilities against a maximum $500,000 in assets) reflected an extreme cash crisis in the brutal funding environment for gene and cell therapies. Founded in 2019 as a spin-off from Applied StemCell, the company operated for approximately six years before collapse. Chief Medical Officer Oscar Segurado departed months after the January 2024 patient dosing announcement, a red flag for the program's viability. Multiple employees displayed "#OpenToWork" banners on LinkedIn profiles. The company provided no clinical trial updates to the federal government since 2023.
Context: The bankruptcy occurred despite (or perhaps exacerbated by) Robert F. Kennedy Jr.'s expressed support for the gene and cell therapy field as HHS Secretary.
Outcome: CEO Ruhong Jiang filed the sparse Chapter 7 petition, prompting a court clerk request for additional information. The company is seeking to liquidate all remaining assets through a bankruptcy trustee.
Filing date: November 24, 2025 (today)
Type: Chapter 11 Section 363 asset sale (Delaware)
Assets/Liabilities: $1-10 million / $50-100 million
Market cap at filing: $14.08 million
The Alpharetta, Georgia-based biopharmaceutical company filed for bankruptcy protection this morning to pursue a rapid asset sale, with stock plummeting 70% to $0.82 in premarket trading.
Pipeline at collapse: Clearside's proprietary SCS® (suprachoroidal space) injection platform and SCS Microinjector delivered therapies to the back of the eye for sight-threatening diseases. Lead candidate CLS-AX (axitinib injectable suspension) was in Phase 2b clinical trials for wet age-related macular degeneration (AMD) and diabetic retinopathy. The company had IND-ready programs for geographic atrophy (GA) and diabetic macular edema (DME). Clearside also marketed XIPERE commercially and held multiple suprachoroidal licensing agreements with royalty arrangements linked to a royalty sub with a $106.5 million revenue cap.
Why it failed: The company issued going concern warnings in its November 14, 2024 quarterly filing, stating it could not continue without additional funding or a strategic transaction. Despite exploring sales, licensing, or partnerships since July 2024, the company failed to secure capital. Financial metrics were dire: operating margin of -689.76%, net margin of -780.9%, and an Altman Z-Score of -48.16 (indicating extreme bankruptcy risk). Revenue declined 64.3% on a 3-year basis. Stock had fallen 80.91% year-to-date and 83.21% over 12 months. Q3 2024 losses totaled $1.14 per share.
Outcome: The company will conduct a Section 363 auction for asset sales free and clear of liens. Legal counsel includes Cooley LLP and Richards, Layton & Finger, P.A. Berkeley Research Group LLC (BRG) serves as financial advisor, with Epiq Bankruptcy Solutions LLC as claims agent. CEO George Lasezkay emphasized the company's "attractive assets" and "clinically proven" platform technology. Normal operations continue during the process. The single analyst covering the stock maintains a Hold rating with no price target.
Filing date: June 10, 2024 (included for 2025 context)
Type: Bankruptcy approved by Tribunal de l'Entreprise of Liège
Country: Belgium
Belgium's women's health pharmaceutical specialist filed for bankruptcy after share prices plummeted over 90% and the company exhausted all options to extend its cash runway.
Products: Estelle (estetrol-E4/drospirenone) contraceptive marketed as Nextstellis in the US and Drovelis in the EU. Donesta, a menopause treatment, produced positive Phase III results in mid-2023 with estetrol (E4) hormone therapy slated for US approval in 2024 and EU approval in 2025.
Why it failed: Failed attempts to raise capital, including an unsuccessful $13.7 million capital raise from selling its stake in Mayne Pharma. The company had no working capital to pursue activities. A transaction with Hungary's Gedeon Richter for €175 million ($188.2 million) provided funds only sufficient to repay creditors, creating no value for shareholders.
Outcome: Gedeon Richter acquired subsidiaries Neuralis and Estetra plus the estetrol portfolio for €175 million. CDMO and Novalon SA entities became subject to separate judicial reorganization proceedings.
Filing date: April 9, 2024 (included for 2025 context)
Type: Bankruptcy declared by Södertörns District Court
Country: Sweden
The Huddinge-based clinical-stage biotech developing autologous natural killer (NK) cell-based cancer therapies filed for bankruptcy after exhausting fundraising options in Europe's frozen capital markets.
Pipeline: Lead candidate Evencaleucel was in Phase II clinical study combining with CD38 monoclonal antibody isatuximab as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients. The European Medicines Agency's Committee for Advanced Therapies issued a scientific recommendation in January 2024, just months before bankruptcy. The technology platform expanded and activated patients' own NK cells for treatment of hematological malignancies and solid tumors. A collaboration with Karolinska University Hospital advanced programs for acute myeloid leukemia (AML).
Why it failed: Founded in 2011, XNK couldn't raise capital over the last year despite extensive efforts. Management described European/Swedish financial markets as "ice cold" for biotech investment. With 95% of spending on research and no income generated, the company burned cash monthly. Potential financiers in Europe limited investments, and markets proved unwilling to take sufficient risk on biotech ventures during 2023-2024.
Outcome: BioLamina purchased the GMP facility for approximately $2 million in May 2024. NOK Therapeutics Inc. (US-based) acquired intellectual property and patents in late May 2024. Anders Svensson Clark of DLA Piper served as bankruptcy trustee.
Filing date: August 12, 2024 (included for 2025 context)
Type: Bankruptcy granted by Gothenburg District Court; delisted from Nasdaq First North Growth Market
Country: Sweden
Scandinavia's sole producer and developer of engineered gold nanoparticles filed for bankruptcy after two years of unsuccessful fundraising in difficult financial markets.
Products and pipeline: StemCART, a stem cell therapy for joint repair and early cartilage damage to prevent osteoarthritis. CellRACE, a cancer diagnostic to predict metastasis. The company's patented surface nanotechnology platform enabled cell-based products and processes in life sciences.
Why it failed: Facing continued development costs requiring significant capital increases to advance projects, multiple smaller capital raises proved insufficient to maintain sustainable operations. Cash runway was expected to last only until August 2024. The company's appeal of rejection from the EIC Accelerator program proved unsuccessful. Unable to secure necessary funding to take projects to clinical stage despite the unique technology platform.
Outcome: Johan Sölveland of Ackordcentralen Väst AB was appointed as bankruptcy trustee to oversee liquidation.
Filing date: August 12, 2025
Type: Companies' Creditors Arrangement Act (CCAA) filing to Ontario Superior Court of Justice
Country: Canada
The specialty pharmacy chain and clinics operator filed for Canadian bankruptcy protection after an aggressive debt-fueled expansion strategy collapsed under the weight of $76 million in creditor obligations.
Services: Operating 17 specialty pharmacies and 19 clinics across Canada with over 200 employees, SRx served patients with HIV/AIDS, cancer, liver diseases, and other complex disorders. The company ran clinical research trials and developed a proprietary Salesforce-based Patient Support Program (PSP) operation for pharmaceutical companies, signing a contract with South Korea's Celltrion in early 2025 to provide PSP services to 9,000+ patients.
Why it failed: Founded in 2013 by pharmacist Adesh Vora, SRx pursued an aggressive "roll-up strategy" beginning September 2023, obtaining $55 million in credit facilities from Canadian Western Bank. The company went into default by December 2023 after just three months. Management invested $10 million developing the PSP operation despite cash flow problems at the pharmacy and clinic levels. The company couldn't hire sufficient staff to meet Celltrion contract requirements and exited the contract by June 2025. Failed attempts to go public through a Canadian reverse takeover and US reverse merger consumed millions of dollars. As Vora stated, the company "planned for a world that no longer exists" and couldn't carry loans in the new economic environment.
Financial position: Listed $99.5 million in assets and $66.2 million in liabilities as of September 30, 2024, with at least $76 million owing to creditors including $1.4 million in unpaid invoices to Advanz Pharma Canada.
Outcome: Court approved expedited sales process on August 21, 2025. PurposeMed (Calgary virtual-care company) purchased the pre-1954 pharmacy charter and Wellesley Street Toronto location. The company had been acquired by US pet-food company Better Choice in April 2025 for US$125 million, with the NYSE ticker changed to SRXH, making the rapid collapse particularly stunning.
The 2025 bankruptcy wave represents far more than isolated company failures—it reflects a fundamental restructuring of biotech financing following the pandemic-era bubble. The numbers tell a stark story: biotech venture capital plummeted from $7 billion in Q1 2025 to $4.8 billion in Q2, the lowest quarterly total in three years. First financings for new biotech startups cratered from $2.6 billion to just $900 million—the lowest in five quarters. New biotech startup formation in the US hit a decade low, down 70% from the 2021 peak.
Companies that went public during the 2020-2021 boom have been decimated. The median stock price for the 2024 IPO class fell 70% through mid-2025. Only 2 of the top 8 funding rounds included new crossover investors, reflecting broad retreat by the hybrid VC/public market investors who fueled the previous boom. One Atlas Venture partner revealed having "lost almost $100 million on paper" over a 20-year career, highlighting the wealth destruction across the sector.
The debt crisis proved particularly brutal. Many companies took on significant debt financing during the pandemic when interest rates sat near zero, a departure from biotech's traditional equity-only capital structures. As the Federal Reserve raised rates, debt service costs exploded—Synthego's interest burden expanded more than 10x from 2020-2021 levels by end of 2023. Companies that seemed well-capitalized suddenly found themselves unable to service debt, triggering covenant violations and lender actions like the $14.66 million sweep that toppled Omega Therapeutics.
Clinical trial failures compounded financial stress. When Seelos Therapeutics' ALS candidate missed its primary endpoint in March 2025, the company had no financial cushion to pursue alternative programs. The same pattern emerged across companies—single program failures that would have been survivable in the 2020-2021 funding environment became extinction events in 2025's capital drought. Even positive clinical results couldn't save companies; Kiromic BioPharma achieved 15-month progression-free survival in its lead patient yet still liquidated for lack of funding.
The crisis disproportionately hit certain technology modalities. Cell and gene therapies proved especially vulnerable due to their capital-intensive manufacturing requirements, long development timelines, and complex regulatory pathways. ASC Therapeutics liquidated despite FDA Fast Track Designation, Orphan Drug Designation, EMA positive opinion, and an active Phase 1/2 trial with patients dosed—a stunning failure that would have seemed impossible just three years earlier. Synthego's collapse despite serving 25% of global cell and gene therapy companies demonstrates how the capital crunch rippled through the entire ecosystem.
European biotechs faced even grimmer conditions. XNK Therapeutics management described Swedish capital markets as "ice cold," with potential financiers unwilling to take risks despite promising clinical programs. The company operated with 95% of spending on research and zero revenue—a model that worked during the boom but became instantly unviable when European VC investment dried up. UK biotech raised £1.23 billion in the first half of 2025, but European biotech funding overall fell 40% quarter-on-quarter.
Regulatory uncertainty added another layer of stress. The appointment of Robert F. Kennedy Jr. as HHS Secretary created unpredictability around FDA decisions, despite his stated support for some technologies like gene therapy. Former FDA Commissioner Robert Califf declared in April 2025 that "the FDA as we've known it is finished," reflecting the scale of anticipated changes. Companies struggling to time capital raises around regulatory milestones found themselves unable to predict when or if key approvals would come.
The "tip of the iceberg" phenomenon means these 12 confirmed Chapter 7 and Chapter 11 filings represent only the most visible failures. Ropes & Gray bankruptcy expert Cristine Schwarzman notes that "many more biotechs go through ABC [Alternative Business Closure] proceedings and just dissolve, because those processes are less expensive and quicker." The true number of 2025 failures likely exceeds 30-40 companies when including quiet wind-downs, voluntary liquidations, and companies that simply stopped operations without formal bankruptcy proceedings.
The 2025 pharmaceutical and biotechnology bankruptcy wave represents the painful but perhaps necessary correction of a sector that overextended during the pandemic. With at least 12 confirmed US bankruptcies through November plus 4 international insolvencies in 2024-2025, the distress continues at near-record levels matching 2023's 14 filings and 2024's 13 filings—far above the historical average of 7-9 annually.
What emerges is a fundamentally reshaped industry. The companies that survived possess stronger balance sheets, more advanced clinical programs, and partnerships with deep-pocketed strategic investors. The collapsed firms' assets—valuable intellectual property, clinical data, and technology platforms—are being acquired at steep discounts by better-capitalized buyers. Regeneron's $256 million acquisition of 23andMe's genetics database, Immunocell's purchase of Kiromic's GDT cell platform, and NOK Therapeutics' acquisition of XNK's NK cell IP all demonstrate how innovation continues even as original companies fail.
Yet the human cost is severe. Thousands of scientists, clinicians, and staff lost their jobs. Patients enrolled in clinical trials faced disruption or termination of their treatment. The consolidation creates less diversity in therapeutic approaches and fewer shots on goal against difficult diseases. The funding drought means breakthrough science developed over decades sometimes can't reach patients who desperately need it.
Looking ahead, experts predict bankruptcies will remain elevated through 2026 as interest rates stay elevated, public markets continue to disfavor biotech, and the regulatory environment remains uncertain. The Series B crunch—described as "the hardest asset class to raise for across any industry"—suggests many current preclinical and Phase 1 companies will never reach pivotal trials. Those that do survive will operate with greater financial discipline, focus on capital-efficient development strategies, and seek Big Pharma partnerships earlier. The biotech boom of 2020-2021 now appears as an aberration, and the sector faces a long rebuilding process to restore investor confidence.